Wealth Enhancement Advisory Services’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$138K Buy
19,294
+563
+3% +$5.31K ﹤0.01% 3865
2026
Q2
$236K Buy
+18,731
New +$214K ﹤0.01% 3436

Other funds holding PHAT

Wealth Enhancement Advisory Services's PHAT Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Phathom Pharmaceuticals (PHAT) stake by 3% in Q3 2026, buying an estimated $5.31K and bringing the position to 19,294 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #3865.

Wealth Enhancement Advisory Services first reported a position in PHAT in Q2 2026 and has held it in 2 quarters since. The position peaked at $236K in Q2 2026. 161 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • Wealth Enhancement Advisory Services held 19,294 shares of Phathom Pharmaceuticals worth $138K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 563 Phathom Pharmaceuticals shares in Q3 2026, an estimated $5.31K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3865 holding.
  • Wealth Enhancement Advisory Services first reported a position in Phathom Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Wealth Enhancement Advisory Services's Phathom Pharmaceuticals position peaked at $236K in Q2 2026.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.